With its FDA approval, the selective histamine 3 receptor antagonist/inverse agonist, branded Wakix, is the first and only therapy for narcolepsy which is not scheduled as a controlled substance by the DEA. It is expected to enter the market by Q4 2019.
Shifting his focus to treatment, Karl Doghramji, MD, shares insight on nonpharmacologic management of insomnia.

SAP Partner Banner

About NeurologyLive's Sleep Medicine Clinical Focus page:

Content found within NeurologyLive's Sleep Medicine Clinical Focus page offers the latest and most valuable information on emerging therapies for sleep disturbances and disorders. Articles include relevant updates from the floor of the most notable neurology conferences and annual meetings, as well as video interviews with the leading experts in neurology, especially those specializing in the treatment of narcolepsy and obstructive sleep apnea.
A lack of sleep has proven to be damaging to physical, mental, and emotional health, and the content offered on this page, which includes breaking news coverage of approvals from the U.S. Food and Drug Administration (FDA), key takeaways from recent clinical trials of new and emerging therapies, and notifications of updates to clinical guidelines, is intended to dramatically improve patient care.